Innoviva Past Earnings Performance
Past criteria checks 1/6
Innoviva's earnings have been declining at an average annual rate of -15%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 4.8% per year. Innoviva's return on equity is 26.6%, and it has net margins of 57.9%.
Key information
-15.0%
Earnings growth rate
-4.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 4.8% |
| Return on equity | 26.6% |
| Net Margin | 57.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Innoviva makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 310 | 180 | 98 | 0 |
| 30 Sep 23 | 290 | 50 | 84 | 0 |
| 30 Jun 23 | 290 | 233 | 83 | 0 |
| 31 Mar 23 | 318 | 233 | 71 | 0 |
| 31 Dec 22 | 331 | 214 | 58 | 0 |
| 30 Sep 22 | 373 | 293 | 46 | 0 |
| 30 Jun 22 | 404 | 99 | 21 | 0 |
| 31 Mar 22 | 396 | 188 | 13 | 0 |
| 31 Dec 21 | 392 | 266 | 16 | 0 |
| 30 Sep 21 | 375 | 309 | 17 | 0 |
| 30 Jun 21 | 365 | 265 | 17 | 0 |
| 31 Mar 21 | 344 | 253 | 16 | 0 |
| 31 Dec 20 | 337 | 224 | 12 | 0 |
| 30 Sep 20 | 322 | 216 | 8 | 0 |
| 30 Jun 20 | 299 | 228 | 9 | 0 |
| 31 Mar 20 | 285 | 189 | 11 | 0 |
| 31 Dec 19 | 261 | 157 | 15 | 0 |
| 30 Sep 19 | 265 | 375 | 17 | 0 |
| 30 Jun 19 | 261 | 382 | 13 | 0 |
| 31 Mar 19 | 264 | 399 | 13 | 0 |
| 31 Dec 18 | 261 | 395 | 19 | 0 |
| 30 Sep 18 | 251 | 190 | 17 | 0 |
| 30 Jun 18 | 238 | 166 | 24 | 0 |
| 31 Mar 18 | 229 | 147 | 30 | 0 |
| 31 Dec 17 | 217 | 134 | 32 | 0 |
| 30 Sep 17 | 191 | 101 | 35 | 0 |
| 30 Jun 17 | 176 | 92 | 32 | 0 |
| 31 Mar 17 | 150 | 72 | 28 | 0 |
| 31 Dec 16 | 134 | 60 | 23 | 0 |
| 30 Sep 16 | 113 | 38 | 22 | 0 |
| 30 Jun 16 | 93 | 19 | 22 | 0 |
| 31 Mar 16 | 71 | -4 | 21 | 0 |
| 31 Dec 15 | 54 | -19 | 20 | 0 |
| 30 Sep 15 | 38 | -39 | 21 | 0 |
| 30 Jun 15 | 26 | -56 | 25 | 0 |
| 31 Mar 15 | 16 | -68 | 29 | 0 |
| 31 Dec 14 | 8 | -74 | 35 | 0 |
| 30 Sep 14 | 3 | -66 | 35 | 0 |
| 30 Jun 14 | 2 | -55 | 32 | 0 |
| 31 Mar 14 | 2 | -9 | 27 | 0 |
| 31 Dec 13 | 5 | -31 | 24 | 0 |
| 30 Sep 13 | 9 | -53 | 26 | 0 |
| 30 Jun 13 | 10 | -78 | 27 | 0 |
Quality Earnings: HVE has a large one-off gain of $61.4M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: HVE's current net profit margins (57.9%) are lower than last year (64.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HVE's earnings have declined by 15% per year over the past 5 years.
Accelerating Growth: HVE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: HVE had negative earnings growth (-16%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (3.5%).
Return on Equity
High ROE: HVE's Return on Equity (26.6%) is considered high.